Daljit Singh Aurora Sells 114,703 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 114,703 shares of the company’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $2.68, for a total value of $307,404.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Neumora Therapeutics Trading Down 1.5%

NASDAQ:NMRA opened at $2.65 on Friday. Neumora Therapeutics, Inc. has a 12-month low of $0.61 and a 12-month high of $11.77. The firm has a market cap of $442.79 million, a PE ratio of -1.80 and a beta of 2.98. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The stock has a fifty day moving average price of $2.08 and a 200 day moving average price of $1.50.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Sell-side analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NMRA. Needham & Company LLC raised their target price on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a report on Tuesday, September 16th. Guggenheim raised shares of Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Monday, October 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Neumora Therapeutics has an average rating of “Hold” and an average target price of $7.43.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. XTX Topco Ltd boosted its stake in Neumora Therapeutics by 969.7% in the first quarter. XTX Topco Ltd now owns 233,597 shares of the company’s stock valued at $234,000 after acquiring an additional 211,759 shares in the last quarter. Graham Capital Management L.P. lifted its holdings in shares of Neumora Therapeutics by 1,643.7% in the 1st quarter. Graham Capital Management L.P. now owns 1,162,499 shares of the company’s stock valued at $1,162,000 after purchasing an additional 1,095,830 shares during the last quarter. Federated Hermes Inc. acquired a new stake in shares of Neumora Therapeutics in the 1st quarter valued at about $285,000. Nuveen LLC acquired a new stake in shares of Neumora Therapeutics in the 1st quarter valued at about $221,000. Finally, Cerity Partners LLC grew its stake in Neumora Therapeutics by 24.0% during the 1st quarter. Cerity Partners LLC now owns 302,505 shares of the company’s stock worth $303,000 after buying an additional 58,597 shares during the last quarter. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.